medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Number 2

<< Back Next >>

Ann Hepatol 2011; 10 (2)

Aminoguanidine potentiates the hepatoprotective effect of silymarin in CCL4 treated rats

Fahmy AA, Fouad MM, Arafat OM, El-Fathaah EA

Language: Spanish
References: 56
Page: 207-215
PDF size: 552.45 Kb.


ABSTRACT

This study examined the possible hepatoprotective effect of aminoguanidine in comparison with silymarin and investigated the possible beneficial effects of the combination of aminoguanidine and silymarin on CCL4-induced liver fibrosis. Male Wister albino rats were randomly divided into five groups (10 rats/group). Group I included control rats injected only with liquid paraffin and saline; group II represents CCL4 control (injected with CCL4 3 times a week for 6 weeks in a dose of 25µl/100gm.b.w i.p, diluted 1:6 with liquid paraffin); group III treated with aminoguanidine (100 mg/kg); group IV was given silymarin (100 mg/kg); group V was given aminoguanidine (100 mg/kg) and silymarin (100 mg/kg). Fibrosis was depicted histologically and biochemically. CCL4 increased serum liver enzymes (ALT, AST, and ALP), lactate dehydrogenase (LDH), level of nitric oxide (NO), tumor necrosis factor alpha (TNFα) and liver malondialdehyde content (MDA), collagen fiber percent and decreased liver reduced glutathione (GSH) content as endogenous antioxidant. Histopathological changes induced by CCL4 include regenerative nodules, deteriorated parenchyma; the lobules were infiltrated with fat and structurally altered. Aminoguanidine, silymarin and their combination reduced these changes and attenuated the pathological effects of CCL4 induced liver injury. The combination of both drugs was better than each drug alone. It is concluded that aminoguanidine has protective effect against CCL4 induced hepatoxicity via its iNOS inhibition and antioxidant effects. In addition, the combination of AG with silymarin has more potent hepatoprotective effect than each drug alone.


REFERENCES

  1. Guyton AC, Hall JE. The liver as an organ. In: Guyton AC, Hall JE (eds.). Textbook of Medical Physiology. 11th Ed. Philadelphia: Saunders Elsevier; 2006, p. 859-64.

  2. Friedman SL. Hepatic fibrosis. In: Schiff ER, Sorrell MF, Maddrey WC (eds.). Schiff‘s Diseases of the Liver. 9th Ed. Philadelphia. Lippinocott Williams & Wilkins; 2003. p: 409-27.

  3. McCafferty D M, Mudgett J S, Swain M G, Kubes P. Inducible nitric oxide synthase plays a critical role in resolving intestinal inflammation. Gastroenterology 1997; 112: 1022-7.

  4. Hortelano S, López-Collazo E, Bosc L. Protective effect of cyclosporin A and FK506 from nitric oxide-dependent apoptosis in activated macrophages. Br J Pharmacol 1999; 126: 1139-46.

  5. Ischiropoulos H, Zhu L, Beckman J S. Peroxynitrite formation from macrophage-derived nitric oxide. Arch Biochem Biophys1992; 298: 446-51.

  6. Radi R, Bechman JS, Bush KM, Freeman B. Peroxynitrite Oxidation of Sulfhydryls: the cytotoxic potential of superoxide and nitric oxide. J Biol Chem 1991; 266(7): 4244-50.

  7. Ischiropoulos H, Zhu L, Chen J, Tsai M, Martin JC, Smith CD, Beckman J S. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 1992; 298: 431-7.

  8. Heller J, Sogni P, Barriere E, et al. Effects of lipopolysaccharide on TNF-α production, hepatic NOS2 activity, and hepatic toxicity in rats with cirrhosis. J Hepatol 2000; 33: 376-81.

  9. Liu S H, Tzeng H P, Kuo ML, Lin-Shiau SY. Inhibition of inducible nitric oxide synthase by β-lapachone in rat alveolar macrophages and aorta. Br J Pharmacol 1999; 126: 746-50.

  10. Kang DG, Kim JW, Lee J. Effects of nitric oxide synthesis inhibition on the Na, K-ATPase activity in the kidney. Pharmacol Res 2000; 41: 123-7.

  11. Giri SN, Biring I, Nguyen T. Abrogation of bleomycin-induced lung fibrosis by nitric oxide synthase inhibitor, aminoguanidine in mice. Nitric Oxide 2002; 7: 109-18.

  12. Doglru-Abbasogllu S, Balkan J, Cevikbas U, Aykac-Toker G, Uysal M. Aminoguanidine, an inducible nitric oxide synthase inhibitor, plus N- acetylcysteine treatment reduce the lipopolysaccharide-augmented hepatotoxicity in rats with cirrhosis. Human& Experimental Toxicology 2002; 21: 359-64.

  13. Valenzuela A, Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res1994; 27: 105-12.

  14. Morazzoni P, Bombardelli E. Silybum marianum (Carduus marianus). Fitoterapia1995; 10: 3-42.

  15. Halim AB, El-Ahmady O, Hassab-Allah S, Abdel-Galil F, Hafez Y, Darwish A. Biochemical effect of antioxidants on lipids and liver function in experimentally induced liver damage. Ann Clin Biochem1997; 34: 656-63.

  16. Farghali H, Kamenikova L, Hynie S, Kmonickova E. Silymarin effects on intracellular calcuim and cytotoxicity: a study in perfused rat hepatocytes after oxidative stress injury. Pharmacol Res 2002; 41: 231-7.

  17. Lieber CS, Leo MA, Cao Q, Ren C, DeCarli LM. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 2003; 37: 336-9.

  18. Riely V. Adaptation of orbital bleeding technique to rapid serial blood studies. Proc Exp Biol Med 1960; 104: 751-4. In: Grad SC, Chenglis CP (eds.). Animal models in toxicology. New York; Marcel Dekker; 1992; pp. 21-164..

  19. Sorg DA, Buckner B. A simple method of obtaining venous blood from small laboratory animals. Proc Soc Exp Biol Med 1964; 115: 1131-1132. In: Animal models in toxicology New York (Grad SC and Chenglis CP eds.). Marcel Dekker; 1992, pp. 21-164.

  20. Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol1957; 28: 56-63.

  21. Young DS, Pestaner LC, Gibberman V. Effect of drug on clinical laboratory tests. Clin Chem 1975; 21: D431-D432.

  22. Beutler E, Durgun O, Kelly B M. Improved method for the determination of blood glutathione. J Lab Clin Med 1963; 51: 882-8.

  23. Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clinica. Chimica Acta 1978; 90: 37-43.

  24. Vassault A. Lactate dehydrogenase. UV-method with pyruvate and NADH. 1982. In: Bergmeyer J, Grabl M, (eds.). Methods of Enzymatic Analysis. Deerfield Beach Florida: Verlag-Chemie; 1983, p. 119-26.

  25. Gogos, et al. 1982.

  26. Crookham JN, Dapson RW. Hazardous chemicals in the histopathology laboratory. In. Regulations, Risks, Handling & Disposal. 1st Ed. An-atech, Battle Creek, MI. 1991; 94:

  27. Montgomery HAC, Dymock JF. The determination of nitrate in water. Analyst 1961; 86: 414-16.

  28. Yang L, et al. Clinical pathological study on effect of qianggan capsule in treating patients of chronic hepatitis B and liver cirrhosis. Chinese Journal of Integrated Traditional and Western Medicine 2002; 8: 90-4.

  29. Ferencikova R, Cervinkove Z, Drahota Z. Hepatotoxic effect of D-galactosamine and protective role of lipid emulsion. Physiol Res 2003; 52: 73-8.

  30. Chang ML, Yeh CT, Chang PY, Jeng-Chang C. Comparison of murine cirrhosis models induced by hepatotoxin administration and common bile duct ligation. World J. Gastroenterol 2005; 11: 4167-72.

  31. Johnson DE, Kroening C. Mechanism of early Carbon tetrachloride toxicity in cultured rat hepatocytes. Pharmacol Toxicol 2006; 83: 231-9.

  32. Recknagel RO, Glende EA, Dolak JA, Waller RL. Mechanisms of carbon tetrachloride toxicity. Pharmacol Therapeutics 1989; 43: 139-54.

  33. Nevin KG, Vijayammal PL. Effect of Aerva Lanata against hepatotoxicity of carbon tetrachloride in rats. Enviromental toxicology and pharmacology 2005; 20: 471-7.

  34. Prasada RSK, Hariharaq MK. Biochemical methods of studing hepatotoxicity. In hepatotoxicology. Boca Raton; CRC Press; 1991, p. 241-326.

  35. Sengottuvelu S, Duraisami S, Nandhakumar J, Duraisami R, Vasudevan M. Hepatoprotective activity of Camellia sinensis and its Possible Mechanism of Action. IJPT 2008; 7: 9-14.

  36. Chen L, Pan D, Zhou J, Jiang YZ. Protective effect of selenium- enriched lactobacillus on CCl4-induced liver injury in mice and its possible mechanisms. World J Gastroenterology 2005; 11: 5795-800.

  37. Shi J, Aisaki K, Ikawa Y, Wake K. Evidence of hepatocyte apoptosis in rat liver after the administration of carbon tetrachloride. Am J Pathol 2007; 153: 515-25.

  38. Ashok ShK, Somayaji SV, Bairy KL. Hepatoprotective effects of Ginkgo biloba against carbon tetrachloride induced hepatic injury in rats. Ind J Pharmacol 2001; 33: 260-6.

  39. Al-Shabanah OA, Alam K, Nagi MN, Al-Rikabi AC, Al- Bekairi AM. Protective effect of aminoguanidine, a nitric oxide synthase inhibitor, against carbon tetrachloride induced hepatotoxicity in mice. Life Sci 2000; 66: 265-70.

  40. Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 1999; 19: 129-40.

  41. Kovalovich K, DeAngelis RA, Li W, Furth E, Ciliberto G, Taub R. Increased toxin-induced liver injury and fibrosis in interleukin- 6-deficient mice. Hepatology 2000; 31: 149-59.

  42. Chamulitrat W, Blazka ME, Jordan SJ, Luster MI, Mason PR. Tumor necrosis factor-α and nitric oxide production in endotoxin-primed rats administered carbon tetrachloride. Life Sci 1995; 24: 2273-80.

  43. Korda M, Yaroshenko TY. The effect of iNOS inhibitor N-(3- (Aminomethyl) benzyl) acetamidine on the hepatotoxicity of allyl alcohol. Med Chem 2004; 6: 114-19.

  44. Powell DW. Myofibroblasts: Paracrine cells important in health and disease. Trans Am Clin Climatol Assoc 2000; 111: 271-92.

  45. Friedman S L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-50.

  46. Mustafa A, Gado AM, Al-Shabanah OA, Al-Bekairi AM. Protective effect of aminoguanidine against paraquatinduced oxidative stress in the lung of mice. Comp Biochem Physiol Part C 2002; 132: 391-7.

  47. Szabo C, Ferrer-Sueta G, Zingarelli B, Southan GJ, Takashi H, Miho G, Hiroyuki S, et al. Yellow tea is more potent than other types of tea in suppressing liver toxicity induced by carbon tetrachloride in rats. Phytother Res 2007; 21: 668-70.

  48. Raza M, Ahmad M, Gado A, Al-Shabanah O A. A comparison of hepatoprotective activities of aminoguanidine and N-acetylcysteine in rat against the toxic damage induced by azathioprine. Comp Biochim Physiol Part C 2003; 134: 451-6.

  49. Sonnenbichler J, Goldberg M, Hane L, et al. Stimulatory effect of silibinin on the DNA synthesis in partially hepatectomized rat livers: non-response in hepatoma and other malignant cell lines. Biochem Pharmacol 1986; 35: 538-41.

  50. Song Z, Deaciuc I, Song M, Lee D Y-W, Liu Y, Ji X, McClain C. Silymarin Protects Against Acute Ethanol-Induced Hepatotoxicity in Mice. Alcohol Clin Exp Res 2006; 30: 407-13.

  51. Muriel P, Mourelle M. Prevention by silymarin of membrane Alterations in acute CCl4 liver damage. J Appl Toxicol 1990; 10: 275-84.

  52. Dehmlow C, Erhard J, De Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996; 23: 749-54.

  53. Malih F, Hosseini-Tabatabaei A, Esmaily H, Khorasani R, Baeeri M, Abdollahi M. Improvement of inflammatory and toxic stress biomarkers by silymarin in a murine model of type one diabetes mellitus. Central European Journal of Biology 2009; 4: 369-80.

  54. Jeong DH, Lee GP, Jeong WI, Do SH, Yang HI, Yuan DW, Park HY, Kim KJ, Jeong KS. Alterations of mast cells and TGB-beta1 on the silymarin treatment for CCL4-induced hepatic fibrosis. World Journal of Gastroenterology 2005; 28: 1141-8.

  55. Fuchs E C, Weyhenmeyer R, Weiner O H. (1997): Effects of silibinin and of a synthetic analogue on isolated rat hepatic stellate cells and myofibroblasts. Arzneimittelforschung 1997; 47: 1383-7.

  56. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18




2020     |     www.medigraphic.com